CVOC-200 Tablet delivers broad-spectrum oral antibacterial therapy for patients with bacterial infections of the respiratory, urinary, and gastrointestinal tract. Formulated with Cefixime 200 mg, a third-generation cephalosporin, it works by inhibiting bacterial cell wall synthesis, ensuring strong bactericidal activity and effective clearance of infection. Its convenient oral formulation makes it an ideal choice for outpatient and follow-up care.
CVOC-200 is highly effective in the treatment of acute bronchitis, community-acquired pneumonia, urinary tract infections, pharyngitis, tonsillitis, otitis media, and uncomplicated gonorrhea. With its proven activity against both Gram-positive and Gram-negative organisms, including resistant strains, it offers clinicians a reliable oral therapy option with a favorable safety profile.
Backed by clinical data, CVOC-200 demonstrates excellent cure rates, faster symptomatic relief, and reduced recurrence in chronic bacterial infections. Its high bioavailability and sustained plasma levels ensure effective therapy with once or twice daily dosing, improving patient compliance and outcomes.
Research & Clinical Data for CVOC-200
Indications Supported by Evidence
- Respiratory Tract Infections (Bronchitis, Pneumonia, Tonsillitis, Pharyngitis): Demonstrated rapid reduction in fever, cough, and throat pain.
- ENT Infections (Otitis Media, Sinusitis): Proven effectiveness in reducing inflammation and bacterial load.
- Urinary Tract Infections: High clinical success rates in uncomplicated and recurrent UTIs.
- Gastrointestinal Infections (Typhoid & Diarrhea): Effective in treating enteric fever and bacterial gastroenteritis.
- Sexually Transmitted Infections: Recommended as a single-dose therapy in uncomplicated gonorrhea.
CVOC-200 Tablet is a safe, trusted, and patient-friendly antibiotic that combines efficacy, convenience, and clinical reliability, ensuring superior infection management and improved quality of life.